Featured Posts
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
City Journal
The FTC Jettisons Economics—and Law
The Federal Trade Commission is stepping up its pursuit of its new favorite bogeyman: Pharmacy Benefit Managers. Two months ago, the FTC issued an …
HeartLand Daily News
FDA Hid COVID Shot Side Effects—Congressional Report
Heartland Daily News cited CEI on COVID public health concerns Joel Zinberg, M.D., senior fellow at the Competitive Enterprise Institute and director of the Public…
Search Posts
Op-Eds
The FDA vs. Commercial Speech
The ability of physicians to prescribe approved medicines for purposes not sanctioned by the Food and Drug Administration (FDA) is one of the most important…
Citation
The 510(k) Program Should Be Saved, Not Scorned
Citation
Economics at Heart of Drug Shortages
Citation
Competitive Enterprise Institute Pleased With PDUFA Recommendations
Citation
Think Tank: More FDA 510(k) Oversight Needed, Driving Innovation Overseas
Citation